Skip to main content

Gyroscope Therapeutics Holdings Ltimited (VISN)

Gyroscope Therapeutics was planning to go public, but the IPO has been postponed.
Stock Price: $20.00 - $22.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading on Invalid Date.
Market Cap613.82M
Revenue (ttm)864,000
Net Income (ttm)-53.17M
Shares Out29.23M
EPS (ttm)-1.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VISN

Gyroscope Therapeutics is a global clinical-stage gene therapy company developing gene therapy beyond rare diseases. Our mission is to preserve sight and fight the devastating impact of blindness. Our science is grounded in the genetic understanding of patients with serious eye diseases to make medicines designed to have a meaningful impact. Our initial focus is age-related macular degeneration, or AMD, one of the leading causes of irreversible blindness, affecting more than 196 million people worldwide. We are developing a differentiated pipel...

IndustryBiological Products
IPO DatePostponed
CEOKhurem Farooq
Employees167
Stock ExchangeNASDAQ
Ticker SymbolVISN
Full Company Profile

Financial Performance

In 2020, VISN's revenue was $864,000, a decrease of -70.87% compared to the previous year's $2.97 million. Losses were -$53.17 million, 58.6% more than in 2020.

Financial Statements

News

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children's Medical Research Institute to Devel...

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics announces research collaboration agreement with Children's Medical Research Institute to develop novel gene therapy capsids.

4 months ago - Business Wire

Gyroscope Therapeutics Postpones Initial Public Offering

Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has postponed plans for its initial public offering.

5 months ago - Business Wire

Gyroscope Therapeutics Announces Launch of Initial Public Offering

Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced that it has launched the roadshow for its initial public...

5 months ago - Business Wire

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States

Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) wi...

6 months ago - Business Wire

Gyroscope Therapeutics IPO Registration Document (S-1)

Gyroscope Therapeutics Holdings Ltimited has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC

With another $148M in the bank, Gyroscope Therapeutics looks to hustle its AMD gene therapy through mid-stage tests

A month and a half later, Gyroscope Therapeutics’ Phase I/II win for its dry-AMD gene therapy is already paying off. On Friday, the biotech took the wraps off a $148 million Series C round to advance th...

7 months ago - Endpoints News